GoodRx Holdings Statistics
Total Valuation
GoodRx Holdings has a market cap or net worth of $960.60 million. The enterprise value is $1.23 billion.
| Market Cap | 960.60M |
| Enterprise Value | 1.23B |
Important Dates
The last earnings date was Tuesday, November 4, 2025, after market close.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GoodRx Holdings has 339.43 million shares outstanding. The number of shares has decreased by -5.60% in one year.
| Current Share Class | 105.47M |
| Shares Outstanding | 339.43M |
| Shares Change (YoY) | -5.60% |
| Shares Change (QoQ) | -2.62% |
| Owned by Insiders (%) | 3.69% |
| Owned by Institutions (%) | 16.94% |
| Float | 93.14M |
Valuation Ratios
The trailing PE ratio is 32.72 and the forward PE ratio is 19.68. GoodRx Holdings's PEG ratio is 1.52.
| PE Ratio | 32.72 |
| Forward PE | 19.68 |
| PS Ratio | 1.30 |
| Forward PS | 1.19 |
| PB Ratio | 1.61 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 5.42 |
| P/OCF Ratio | 5.34 |
| PEG Ratio | 1.52 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.28, with an EV/FCF ratio of 6.95.
| EV / Earnings | 38.80 |
| EV / Sales | 1.54 |
| EV / EBITDA | 9.28 |
| EV / EBIT | 11.44 |
| EV / FCF | 6.95 |
Financial Position
The company has a current ratio of 3.11, with a Debt / Equity ratio of 0.91.
| Current Ratio | 3.11 |
| Quick Ratio | 2.99 |
| Debt / Equity | 0.91 |
| Debt / EBITDA | 3.87 |
| Debt / FCF | 3.07 |
| Interest Coverage | 2.47 |
Financial Efficiency
Return on equity (ROE) is 4.90% and return on invested capital (ROIC) is 5.64%.
| Return on Equity (ROE) | 4.90% |
| Return on Assets (ROA) | 5.03% |
| Return on Invested Capital (ROIC) | 5.64% |
| Return on Capital Employed (ROCE) | 9.42% |
| Revenue Per Employee | $1.08M |
| Profits Per Employee | $43,027 |
| Employee Count | 738 |
| Asset Turnover | 0.60 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GoodRx Holdings has paid $22.00 million in taxes.
| Income Tax | 22.00M |
| Effective Tax Rate | 40.93% |
Stock Price Statistics
The stock price has decreased by -42.13% in the last 52 weeks. The beta is 1.46, so GoodRx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 1.46 |
| 52-Week Price Change | -42.13% |
| 50-Day Moving Average | 3.68 |
| 200-Day Moving Average | 4.27 |
| Relative Strength Index (RSI) | 33.66 |
| Average Volume (20 Days) | 2,813,166 |
Short Selling Information
The latest short interest is 7.58 million, so 2.23% of the outstanding shares have been sold short.
| Short Interest | 7.58M |
| Short Previous Month | 8.25M |
| Short % of Shares Out | 2.23% |
| Short % of Float | 8.14% |
| Short Ratio (days to cover) | 1.31 |
Income Statement
In the last 12 months, GoodRx Holdings had revenue of $800.65 million and earned $31.75 million in profits. Earnings per share was $0.09.
| Revenue | 800.65M |
| Gross Profit | 748.33M |
| Operating Income | 107.76M |
| Pretax Income | 53.75M |
| Net Income | 31.75M |
| EBITDA | 132.72M |
| EBIT | 107.76M |
| Earnings Per Share (EPS) | $0.09 |
Balance Sheet
The company has $273.53 million in cash and $545.14 million in debt, giving a net cash position of -$271.61 million or -$0.80 per share.
| Cash & Cash Equivalents | 273.53M |
| Total Debt | 545.14M |
| Net Cash | -271.61M |
| Net Cash Per Share | -$0.80 |
| Equity (Book Value) | 600.71M |
| Book Value Per Share | 1.76 |
| Working Capital | 383.66M |
Cash Flow
In the last 12 months, operating cash flow was $179.76 million and capital expenditures -$2.44 million, giving a free cash flow of $177.32 million.
| Operating Cash Flow | 179.76M |
| Capital Expenditures | -2.44M |
| Free Cash Flow | 177.32M |
| FCF Per Share | $0.52 |
Margins
Gross margin is 93.46%, with operating and profit margins of 13.46% and 3.97%.
| Gross Margin | 93.46% |
| Operating Margin | 13.46% |
| Pretax Margin | 6.71% |
| Profit Margin | 3.97% |
| EBITDA Margin | 16.58% |
| EBIT Margin | 13.46% |
| FCF Margin | 22.15% |
Dividends & Yields
GoodRx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 5.60% |
| Shareholder Yield | 5.60% |
| Earnings Yield | 3.31% |
| FCF Yield | 18.46% |
Analyst Forecast
The average price target for GoodRx Holdings is $5.48, which is 93.64% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.48 |
| Price Target Difference | 93.64% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 5.22% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GoodRx Holdings has an Altman Z-Score of 1.18 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.18 |
| Piotroski F-Score | 6 |